Baxter Hartmann’s 1000mL Bag Solution Compound Sodium Lactate Infusion Intravenous IV (AHB2324) – Physiological Fluid Resuscitation

Optimise patient recovery timelines and safely manage intravascular volume replacement with the Baxter Hartmann’s 1000mL Bag Solution Compound Sodium Lactate Infusion Intravenous IV (AHB2324). Widely known across healthcare institutions as Compound Sodium Lactate Intravenous Infusion BP, this ultra-pure, isotonic fluid matrix is meticulously formulated to mimic the chemical balance of human plasma. It provides clinical teams with a dependable, fast-acting solution for restoring critical extracellular fluid volume in patients suffering from severe dehydration, surgical fluid loss, or acute trauma.

Advanced Electrolyte Balancing and Acidosis Management

When metabolic changes cause too much acid to accumulate in the blood, choosing the right intravenous fluid is vital. The Baxter Hartmann’s 1000mL Bag Solution Compound Sodium Lactate Infusion Intravenous IV (AHB2324) is specifically engineered to counteract systemic acid imbalances. The sodium lactate component acts as a natural physiological buffer, metabolizing in the liver to form bicarbonate ions that gently raise blood pH back to a stable baseline. Paired with balanced levels of sodium, potassium, and calcium chlorides, it replaces lost mineral salts smoothly without inducing cellular stress or electrolyte shock.

Key Features & Clinical Benefits

• Isotonic Plasma Compatibility: Formulated to exert an osmotic pressure that matches human blood perfectly, preventing standard cellular damage.

• Targeted Acidosis Buffering: Contains sodium lactate to effectively neutralize excess blood acidity resulting from various acute medical complications.

• High-Volume 1-Litre Bag: The generous 1000mL bag configuration provides a large fluid reservoir, ideal for intensive volume expansion and routine intraoperative hydration.

• Preservative-Free Sterility: Formulated with no antimicrobial additives, chemical stabilizers, or heavy buffers—using only high-purity water for injection as its vehicle.

• Premium Flexible Bag Casing: Housed in an ergonomic, shatterproof delivery pouch designed for regular gravity flow or rapid delivery under pressure infusion cuffs.

• Surgical and Post-Operative Support: Serves as an excellent fluid foundation during surgical recovery to support cellular energy production and physiological stability.

Primary Use Cases in Healthcare Facilities

The Baxter Hartmann’s 1000mL Bag Solution Compound Sodium Lactate Infusion Intravenous IV (AHB2324) is standard medical equipment across triage departments, critical care wards, and veterinary surgeries for:

• Replacing massive extracellular fluid losses from severe vomiting, diarrhea, or continuous wound drainage.

• Pre-operative and intraoperative fluid maintenance to lock in stable hemodynamic baselines.

• Treating mild, non-severe forms of metabolic acidosis caused by diminished systemic tissue perfusion.

Product Specifications

Directions for Clinical Administration

Prior to suspending the Baxter Hartmann’s 1000mL Bag Solution Compound Sodium Lactate Infusion Intravenous IV (AHB2324) on your IV pole, inspect the pouch for micro-leaks by squeezing it firmly. Verify fluid clarity against a direct light source; discard the bag immediately if you observe turbidity, discoloration, or floating particulates. Cleanse the integrated administration ports using aseptic hospital protocols before introducing a sterile IV giving set. Adjust the infusion rate according to the patient’s body mass index, specific age profile, and real-time clinical fluid output charts.

Clinical Warning and Storage Guidelines: For intravenous infusion only; strictly non-injectable via other parenterals. Store the Baxter Hartmann’s 1000mL Bag Solution Compound Sodium Lactate Infusion Intravenous IV (AHB2324) below 30°C and prevent exposure to freezing temperatures. Because this formula contains calcium ions, do not co-administer this fluid through the same tubing lines as stored whole blood or plasma to eliminate the risk of clot-inducing pseudo-agglutination.